Enzyme therapy for Fabry disease: Neutralizing antibodies toward agalsidase alpha and beta

Kidney International

Volumn 66, Issue 4, 2004, Pages 1589-1595

  Linthorst, Gabor E ^a   Hollak, Carla E M ^b   Donker Koopman, Wilma E ^b   Strijland, Anneke ^b   Aerts, Johannes M F G ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

Antibodies; Enzyme replacement; Fabry disease; Targeting

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; CLEMASTINE; CORTICOSTEROID; DEXAMETHASONE; GLOBOTRIAOSYLCERAMIDE; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; PARACETAMOL; RECOMBINANT ENZYME;

ADULT; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME THERAPY; FABRY DISEASE; FEMALE; FEVER; HUMAN; HYPERSENSITIVITY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY TUBULE; LEUKOCYTE; MALE; NAUSEA; PRIORITY JOURNAL; VOMITING;

EID: 4644316602     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00924.x     Document Type: Article

References (20)

1. CASADEVALL N, NATAF J, VIRON B, et al: Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 346:469-475, 2002
2. LUSHER JM, ARKIN S, ABILDGAARD CF, et al: Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group. N Engl J Med 328:453-459, 1993
3. BARTON NW, BRADY RO, DAMBROSIA JM, et al: Replacement therapy for inherited enzyme deficiency - Macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324:1464-1470, 1991
4. ENG CM, GUFFON N, WILCOX WR, et al: Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 345:9-16, 2001
5. SCHIFFMANN R, KOPP JB, AUSTIN HA III, et al: Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 285:2743-2749, 2001.
6. VAN DEN HOUT H, REUSER AJ, VULTO AG, et al: Recombinant human alpha-glucosidase from rabbit milk in Pompe patients. Lancet 356:397-398, 2000
7. KAKKIS ED, MUENZER J, TILLER GE, et al: Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344:182-188, 2001
8. DESNICK RJ, IOANNOU YA, ENG ME: α-galactosidase A deficiency: Fabry disease, in The Metabolic and Molecular Bases of Inherited Disease (vol 3), 8th ed, edited by Scriver CR, Beaudet AL, Sly WS, Valle D, New York, McGraw-Hill, 2001, pp 3733-3774
9. THURBERG BL, RENNKE H, COLVIN RB, et al: Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 62:1933-1946, 2002
10. MEHTA A, RICCI R, WIDMER U, et al: Fabry disease defined: Baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur J Clin Invest 34:236-242, 2004
11. BECK M: Agalsidase alfa - A preparation for enzyme replacement therapy in Anderson-Fabry disease. Expert Opin Investig Drugs 11:851-858, 2002
12. PASTORES GM, THADHANI R: Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 358:601-603, 2001
13. MAYES JS, SCHEERER JB, SIFERS RN, et al: Differential assay for lysosomal α-galactosidases in human tissues and its application to Fabry's disease. Clin Chim Acta 112:247-251, 1981
14. FOLCH J, LEES M, SLOANE-STANLEY GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509, 1957
15. ROSENBERG M, KINGMA W, FITZPATRICK MA, et al: Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: Induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93:2081-2088, 1999
16. BRADY RO, MURRAY GJ, OLIVER KL, et al: Management of neutralizing antibody to ceredase in a patient with type 3 Gaucher disease. Pediatrics 100:E11, 1997
17. BROOKS DA, KAKAVANOS R, HOPWOOD JJ: Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 9:450-453, 2003
18. FOOD AND DRUG ADMINISTRATION: FDA briefing document Fabrazyme: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3917B1_03_FDA%20backgrounder. pdf. 2002
19. FOOD AND DRUG ADMINISTRATION: FDA briefing report Replagal: http://www.fda.gov/ohrms/dockets/ac/03/briefing/3917B2'02'FDA-backgrounder.pdf. 2002
20. BLOM D, SPEIJER D, LINTHORST GE, et al: Recombinant enzyme therapy for Fabry disease. Absence of editing of human α-galactosidase A mRNA. Am J Hum Genet 72:23-31, 2003